Updates about our latest science, publications, partnerships, and products.
Please rotate the screen for the best
viewing experience. Thank you.
This website was designed with newer technology in mind. Please update your current browser or switch to a recently updated browser. Thank you.
Our Human Emulation System sets a new standard for recreating true-to-life human biology and is being used to advance product innovation, design, and safety across a range of applications, including drug development, agriculture, cosmetics, food, and chemical-based consumer products.
We are continuously developing a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs, and are also working with clinical partners to produce Organ-Chips personalized with individual patients’ stem cells, for applications in precision medicine and personalized health.
Our founding team pioneered Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. We hold the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for Organs-on-Chips technology and related systems.
James Coon is the CEO of Emulate. He is an accomplished entrepreneur who brings over 20 years of experience in founding life sciences companies, developing new products and executing commercialization strategies.
James Coon is the Chief Executive Officer of Emulate and has been in the biotechnology and pharmaceutical industry for over 20 years. Coon has most recently served as Entrepreneur in Residence at the Wyss Institute for Biologically Inspired Engineering at Harvard University, providing researchers with insights on commercialization and product development, target markets, and fundraising strategies in both Nanotherapeutic and Organs-on-Chips technologies.
Coon has served as a co-founder, executive management, and strategic partner for numerous healthcare and biotech startup companies, including roles as President of RxGen, President and CEO of BCS, Inc., President and CEO of HepatoTech, Inc., Executive Vice-President of CellzDirect (acquired by Invitrogen-Life Technologies), and the Senior Director of Business Development for RTI International.
Earlier in his career, Coon held a range of management positions at Fisons Pharmaceutical, Astra Arcus, AstraZeneca, and GlaxoSmithKline. He received his undergraduate degree in Biochemistry from the Rochester Institute of Technology, and completed his graduate work in liver cell biology at the University of North Carolina at Chapel Hill School of Medicine.
Geraldine A. Hamilton, Ph.D. serves as the President and CSO of Emulate. She is a recognized cell biologist and toxicologist focused on developing and applying innovative cell-based technologies.
Geraldine A. Hamilton is the President and Chief Scientific Officer of Emulate. Prior to joining Emulate’s founding team, she served as Lead Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss Institute, Hamilton lead the Organs-on-Chips program and managed the multidisciplinary team responsible for developing, translating and commercializing the Organs-on-Chips technology.
Hamilton’s career spans industry, academia and the start-up world. Prior to her tenure at Harvard University, Hamilton spent more than 11 years in the pharmaceutical industry in leadership roles managing drug discovery teams. Her research achievements helped advance the development and application of human relevant in vitro models for drug discovery. Hamilton was a founding scientist and VP of Scientific Operations for CellzDirect, a start-up biotech company that specialized in providing cell products to the pharmaceutical industry for safety testing. Hamilton was responsible for the successful translation of CellzDirect’s technology from academia to broad use and acceptance across the industry.
Hamilton received her Ph.D. in cell biology/toxicology from the University of Hertfordshire (England) in conjunction with GlaxoSmithkline, followed by a post-doctoral research fellowship at the University of North Carolina. She has authored more than 40 publications and numerous patents.
Donald Ingber is a pioneer in the field of Organs-on-Chips. The technology emerged from his leadership as the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Donald Ingber is the Scientific Founder and Chair of the Scientific Advisory Board for Emulate. In addition to his Founding Director role at the Wyss Institute, he is the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences.
Dr. Ingber is recognized as a pioneer of the emerging field of biologically inspired engineering, and oversees efforts at the Wyss Institute that strive to identify the mechanisms that living organisms use to self-assemble, and to apply these principles to develop advanced materials and devices for healthcare and the environment. He led the Organs-on-Chips development program at the Wyss Institute that resulted in the creation of Emulate’s automated bioemulation platform. Dr. Ingber has also made major contributions to mechanobiology, tissue engineering, tumor angiogenesis, systems biology, and nanobiotechnology.
Dr. Ingber has authored more than 375 publications and 85 patents, and has received numerous honors, including the NC3Rs Annual Award from the National Centre for the Replacement, Refinement, and Reduction of Animals in Research, and both the Leading Edge Award and Honorary Membership from the Society of Toxicology. He is also a member of both the American Institute for Medical and Biological Engineering and the Institute of Medicine of the National Academies. Ingber received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Daniel Levner, Ph.D. is Emulate’s Chief Technology Officer. He is a recognized engineer and biotechnologist with extensive experience in the commercialization of innovative research.
Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulating innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture.
Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.
Harry Dhaliwal is an accomplished CFO who brings over 30 years of demonstratable experience leading world class financial structures driving cost, speed, and quality (FCCA certified).
Harry Dhaliwal is the Chief Financial Officer of Emulate. He is an accomplished CFO who brings over 30 years of demonstratable experience leading world class financial structures driving cost, speed, and quality (FCCA certified).
Dhaliwal joined Emulate from Barclays Bank (London and New York) where he was the CFO for Barclays ServCo and responsible for implementing a shared center as well as managing the finance operational activities for the combined Retail (UK) and Investment bank (NY). Prior to this, he held various Senior Executive roles at GE Capital and Industrial, including CFO of GE Inc Global Operations and Global Controllership roles across the Capital Business including GE Treasury. Other key commercial roles included the CEO for Yale Material Handling (Holland and UK) where he Increased market share from 1% to 8% in 12 months by improving ‘Go to Market’ strategy and optimizing sales force effectiveness. Improved Customer satisfaction from 66% - 88% and created a financing JV with GE Capital.
Stan King aligns the company with strategic growth opportunities that best enable researchers to understand human biology and improve human health.
Stan King is the Vice President of Corporate Development at Emulate. He aligns the company with strategic growth opportunities that best enable researchers to understand human biology and improve human health. King’s interest in how science can improve society has led him to roles at the interface of business strategy, commercialization, intellectual property, and high-impact biomedical research. Prior to joining Emulate, King worked in business development and licensing roles at Boston Children’s Hospital’s Technology Innovation and Development Office, the Wyss Institute for Biologically Inspired Engineering at Harvard University, the MIT Technology Licensing Office, and UVa Innovation. He’s developed intellectual property and licensing strategies, managed multi-party strategic alliances, and executed deals for a variety of life science technologies, all with the goal of commercializing early-stage research discoveries.
King also founded a social enterprise and worked internationally in Kigali, Rwanda with a non-governmental organization developing strategies to foster an entrepreneurship ecosystem as a country-wide development effort. Stan has a B.S. from Florida A & M University and a Ph.D. from the University of Virginia.
As an ambassador of the company, Megan serves as a liaison for the CEO both internally and externally, including the Board of Directors, Investors, and industry partners.
Megan Connolly is the Chief of Staff to the CEO and oversees the Office of the CEO. As an ambassador of the company, she serves as a liaison for the CEO both internally and externally, including the Board of Directors, Investors, and industry partners. She is responsible for the day to day operations as well as providing strategic direction in regards to administrative, financial, and operational initiatives.
Connolly has served in multiple management roles over the last 8 years within finance, healthcare, and clinical research. Prior to joining Emulate, Megan was at NYU School of Medicine as an Acting Clinical Research Unit Manager and a member of the Association of Clinical Coordination & Research Management (ACCRM) Executive Committee where she directly worked with the university’s IRB to implement and improve clinical research regulations.
Megan has a B.S. in Biological Anthropology with Honors from UMASS Amherst and has a diversified training in project management, first responder medicine (WFR), and clinical research coordination (CCRC).
Stuart Gibb is the Vice President of Sales at Emulate, and has over 20 years of experience working in life science sales in both Europe and the US.
Stuart Gibb is the Vice President of Sales at Emulate, and has over 20 years of experience working in life science sales in both Europe and the US. He is an accomplished leader who brings experience in building and leading successful sales teams.
Most recently, Gibb served as Director of Sales for the Antibody and Immunoassays System Group at Thermo Fisher Scientific. Before that, he worked for 24 years at Becton Dickinson Company (BD) in multiple roles, including European Sales Leader of BD Biosciences-Imaging Systems and Director of Sales for BD Biosciences Flow Cytometry, where he was based in US. His career started in Scotland as a bio-analytical chemist for Scotlab.
Gibb has built successful teams that have provided scientists in biotech, pharma, and academia with effective and relevant tools that help them produce innovative and important research.
Greg Williams is Vice President and General Counsel for Emulate. He has a wealth of experience with high-growth biotechnology companies and in intellectual property law.
Greg Williams is Vice President and General Counsel for Emulate, bringing decades of experience in legal practice in the life sciences sector.
Williams is a former partner in the Intellectual Property Practice Group of Pepper Hamilton LLP, with a focus on intellectual property acquisition and management, including IP asset strategy, contracts, licensing portfolio development and management, patent, trademark, technology transfer and strategic alliance negotiation/restructuring. Previously, Williams served as general counsel and a senior member of the global business development team for New England Biolabs, where he was responsible for business development, organizational management and non-IP affairs oversight (employment, compliance, property, etc.) and strategic counseling.
Williams received his undergraduate degree in Chemistry and Biology from McGill University in Montreal, Canada, and his first law degree from McGill University and a Masters of Law (LL.M.) with specialization in intellectual property and anti-trust law from the University of Pennsylvania Law School.
We collaborate with our community to continuously advance our technology platform so that it can have impact on patient health across disease research, drug discovery and development, regulatory science, and in the clinic.learn more
We offer a great rewards package — including competitive pay, options, and bonuses, as well as excellent health benefits, generous paid time-off, a dynamic culture, and opportunities for career development.
For consideration and to meet with our team, please email your resume directly with a short cover letter explaining why you want to work with us, as well as the position you would like to be considered for, to email@example.com.
Cedars-Sinai Medical CenterRead More
The OS FundRead More
SciFi VCRead More
Atel Ventures, Inc.Read More
Venture capital firm, NanoDimensionRead More
ALS Finding a Cure FoundationRead More
Private investor, Hansjörg WyssRead More
Founders FundRead More
Updates about our latest science, publications, partnerships, and products.
HQ: 27 Drydock Ave, Boston, MA 02210